- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cost of State Insurance Exchange May Be Too High for Some States
The high cost of running a state-based health insurance exchanges created under the Affordable Care Act could lead to states turning over operations to the federal government or joining forces with other states.
The high cost of running a state-based health insurance exchanges created under the Affordable Care Act could lead to states turning over operations to the federal government or joining forces with other states, according to a report from The Associated Press.
In March, Oregon killed its insurance exchange after it wasn't even used during the last open enrollment period. The state’s exchange spent more than $300 million to launch a working website, but Oregon used HealthCare.gov to sign up enrollees during enrollment for the 2015 coverage year and legislature voted in February to close the exchange.
Now Hawaii, which was awarded $205 million in federal startup grants and has spent $139 million, is turning to HealthCare.gov for 2016. Now of the 12 states and the District of Columbia that fully control their markets, about half face financial difficulties, according to experts.
Read more from The Associated Press: http://abcn.ws/1LKpew3
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
